Log in

Actinium Pharmaceuticals Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume409,147 shs
Market Capitalization$151.63 million
P/E RatioN/A
Dividend YieldN/A
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Phone646 677 3870



Sales & Book Value

Annual SalesN/A
Book Value$3.34 per share


Net Income$-21,900,000.00


Market Cap$151.63 million
Next Earnings DateN/A
30 days | 90 days | 365 days | Advanced Chart

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Actinium Pharmaceuticals (ARCA:ATNM) Frequently Asked Questions

What stocks does MarketBeat like better than Actinium Pharmaceuticals?

Wall Street analysts have given Actinium Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Actinium Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Actinium Pharmaceuticals' key competitors?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the following people:
  • Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (Age 56, Pay $861.35k)
  • Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (Age 34, Pay $378.55k)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific & Technology Officer (Age 58, Pay $432.25k)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 65, Pay $490k)
  • Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang, VP & Head of Radiation Sciences
  • Ms. Cynthia Pussinen, Exec. VP of Technical Operations & Supply Chain
  • Dr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale, VP & Global Head of Regulatory Affairs

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the ARCA under the ticker symbol "ATNM."

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $0.00.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is www.actiniumpharma.com.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 MADISON AVENUE 7TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646 677 3870 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.